First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

Abstract Background The [177Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment resistance and disease recurrence. An interesting alternative could be the somatostatin antagonist, [177Lu]Lu-DOTA-JR11, that demonstrat...

Full description

Bibliographic Details
Main Authors: Maryana Handula, Savanne Beekman, Mark Konijnenberg, Debra Stuurman, Corrina de Ridder, Frank Bruchertseifer, Alfred Morgenstern, Antonia Denkova, Erik de Blois, Yann Seimbille
Format: Article
Language:English
Published: SpringerOpen 2023-06-01
Series:EJNMMI Radiopharmacy and Chemistry
Subjects:
SSTR2
DOTA-JR11
Actinium-225
Lutetium-177
Radionuclide therapy
Online Access:https://doi.org/10.1186/s41181-023-00197-0

Internet

https://doi.org/10.1186/s41181-023-00197-0

Similar Items